The association between skeletal muscle measures and chemotherapy-induced toxicity in non-small cell lung cancer patients.
Corine de JongNajiba ChargiGerarda J M HerderSimone W A van HaarlemFemke van der MeerAnne S R van LindertAlexandra Ten HeuvelJan BrouwerPim A de JongLot A DevrieseAlwin D R HuitemaAntoine C G EgbertsRemco de BreeVera H M DeneerPublished in: Journal of cachexia, sarcopenia and muscle (2022)
Non-small cell lung cancer patients with pretreatment low SMM are at significant higher risk for haematological toxicities grade 3/4 and DLT. NSCLC patients with high SMD are at significant lower risk for DLT. Further studies should be aimed to investigate whether platinum dosing based on skeletal muscle measurements and/or improvement of pretreatment SMM/SMD could reduce the risk of toxicity without compromising efficacy.